Tag:

Takeda Pharmaceutical

Latest Headlines

Latest Headlines

Takeda's U.S. chief bows out amid management shake-up

When Takeda Pharmaceutical faced the patent-cliff blues, it brought in Christophe Weber as president and COO to engineer a revamp. And true to his mission, Weber unveiled a new org chart in September, along with a fresh set of top managers.

Contrave demand swamps Takeda's direct-delivery discount program

Private insurers and public payers have refused to cover obesity drugs--or foisted big copays onto patients--dragging down new drugs. So, when Takeda rolled out Orexigen's new obesity drug Contrave a few weeks ago, the Japanese drugmaker also rolled out a direct-delivery program, Direct Save.

Takeda strikes deal with C4X to access 3D drug structure tech

Takeda Pharmaceutical's United Kingdom subsidiary has begun working with C4X Discovery to improve its lead discovery and hit identification. The agreement is centered on C4XD's 3D drug technology, a nuclear magnetic resonance-based method of viewing the structure of a molecule.

Database provides fresh evidence of effect of diabetes drugs on Alzheimer's

This week a German team presented data from a database analysis study that found a link between a diabetes drug and a slight dip in the risk of developing Alzheimer's.

Japanese companies follow Sanofi's lead in shunning Big Pharma M&A trend

In the midst of an unprecedented dealmaking spree that has produced $139 billion in pharmaceutical mergers this quarter alone, one country has been conspicuously absent: Japan. Even such giants as Astellas Pharma and Takeda Pharmaceutical, which have led M&A runs in Japan in the past, have stayed on the sidelines. Why?

Takeda's colitis med Entyvio wins European OK on heels of FDA's approval

Japan's Takeda Pharmaceutical nabbed European approval for its treatment for ulcerative colitis and Crohn's disease, Entyvio, after winning the FDA's blessing last week

Takeda strikes $400M IT services deal with Wipro

Wipro has won a $400 million contract to manage Takeda's infrastructure. Takeda inked the deal to consolidate its operations, with Wipro becoming its primary provider of IT infrastructure management services.

Jury's out in Las Vegas after 3-month trial over Actos cancer risks

In federal court in Las Vegas, a trial over the cancer risks of Takeda's Actos drug wrapped up Tuesday, leaving the jury to decide whether the diabetes remedy triggered the plaintiffs' disease--and if so, how much they should collect from the Japanese drugmaker.

Jury slaps Takeda, Lilly with massive $9B in damages in Actos cancer case

A Louisiana jury pummeled Takeda Pharmaceutical and Eli Lilly & Co. with $9 billion in punitive damages in a liability suit over their blockbuster diabetes drug Actos. It's one for the record books, an amount so far beyond normal that even the victorious lawyers discounted it.

With tough Japanese enforcers eyeing its Blopress marketing, Takeda chief admits missteps

Japan's health ministry is one of the world's toughest when it comes to demanding truth in advertising. Violators can be thrown in prison. And the newest target of its scrutiny is Takeda Pharmaceutical, which is now admitting it may have mismarketed its hypertension drug Blopress.